Hepatitis B

Chapter

Abstract

The discovery of hepatitis B virus (HBV) did not arise from a goal-directed search for this pathogen but from studies in basic science that were initially set on a different path. Much of the early research that resulted in the discovery of the virus, the invention of diagnostics, and the development of a vaccine was conducted at the Division of Clinical Research of Fox Chase Cancer Center (Blumberg et al. 1967). This chapter will focus on this early period and will also include a discussion of the worldwide use of the initial and subsequent vaccines that were associated with dramatic decreases in the incidence and prevalence of acute and chronic HBV infection, the HBV carrier state, and hepatocellular carcinoma (HCC), the latter marking HBV vaccine as the first one to prevent cancer. The nonpathological effects of chronic HBV infection, including a discussion of the relationship of genetic polymorphisms to susceptibility to chronic infection, and the relation of HBV infection to gender selection will conclude the chapter.

References

  1. Allison AC, Blumberg BS (1961) An isoprecipitation reaction distinguishing human serum protein types. Lancet 1:634–637CrossRefPubMedGoogle Scholar
  2. American Cancer Society (2008) Infectious agents and cancer. http://www.cancer.org/docroot/PED/content/PED_1_3X_Infectious_Agents_and_Cancer.asp. Accessed 15 Aug 2008
  3. Bayer ME, Blumberg BS, Werner B (1968) Particles associated with Australia antigen in the sera of patients with leukemia, Down’s syndrome and hepatitis. Nature 218:1057–1059CrossRefPubMedGoogle Scholar
  4. Beeson PB (1943) Jaundice occurring one to four months after transfusion of blood or plasma report of seven cases. JAMA 121:1332–1334Google Scholar
  5. Benahamon E, Courouce AM, Jungurs P et al (1984) Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 3:102–103Google Scholar
  6. Blumberg BS (1961) Inherited susceptibility to disease: Its relation to environment. Arch Environ Health 3:612–636PubMedGoogle Scholar
  7. Blumberg BS (1972) Viral hepatitis, Au antigen, and hope for a vaccine. Gastroenterol Med World News 14–18Google Scholar
  8. Blumberg BS (1990) Proc. International Conference on Prospects for Eradication of Hepatitis B Virus. Vaccine 8 Introduction S5 Conclusion S139Google Scholar
  9. Blumberg BS (2002) Hepatitis B. The hunt for a killer virus. Princeton University Press, Princeton, NJGoogle Scholar
  10. Blumberg BS (2004) The impact of hepatitis B vaccine worldwide. In: Vierucci A (ed) The proceedings of the Società Italiana de Allergolgia ed Immunologia Pediatrica. Editeam Cento, FlorenceGoogle Scholar
  11. Blumberg BS (2006a) Hepatitis B virus: Conjectures on human interactions and the origin of life. In: Seckbach J (ed) Life as we know it. Springer, New YorkGoogle Scholar
  12. Blumberg BS (2006b) The curiosities of hepatitis B virus: Prevention, sex ratio, and demography. Proc Am Thorac Soc 3:14–20CrossRefPubMedGoogle Scholar
  13. Blumberg BS, Alter HJ, Visnich S (1965) A “new” antigen in leukemia sera. JAMA 191: 541–546PubMedGoogle Scholar
  14. Blumberg BS, Melartin L, Guinto RA et al (1966) Family studies of a human serum isoantigen system (Australia antigen). Am J Human Genet 18:594–608Google Scholar
  15. Blumberg BS, Gerstley BJS, Hungerford DA et al (1967) A serum antigen (Australia antigen) in Down’s Syndrome leukemia and hepatitis. Ann Int Med 66:924–931PubMedGoogle Scholar
  16. Blumberg BS, London WT, Sutnick AI (1969) Relation of Australia antigen to virus of hepatitis. Bull Path 10:164Google Scholar
  17. Blumberg BS, Millman I (1972) Vaccine against viral hepatitis and process. US Patent 3,636,191, 18 Jan 1972Google Scholar
  18. Bonnanni P (1995) Implementation in Italy of a universal vaccination program against hepatitis B. Vaccine 13:68–71Google Scholar
  19. Buynak EB, Roehm RR, Tytell AA et al (1976) Development and chimpanzee testing of a vaccine against human hepatitis B. Proc Soc Exp Biol Med 151:694–700PubMedGoogle Scholar
  20. Cameron JDS (1943) Infective hepatitis. Q J Med 12:139–155Google Scholar
  21. CDC (2008) Hepatitis B FAQs for health professional. http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview. Accessed 12 Aug 2008
  22. Chan CY, Lee SD, Lo KJ (2004) Legend of hepatitis B vaccination: The Taiwan experience. J Gastrolenterol Hepatol 19:121–126CrossRefGoogle Scholar
  23. Chen PJ (2008) Hepatitis B virus and hepatocellular carcinoma: Genetics and gender Taipei, Taiwan. Presented at the 2nd International Conference on Viral Oncology, Philadelphia, PA 26 September 2008Google Scholar
  24. Chen JK, Berek JS (2007) Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 25:2975–2982CrossRefGoogle Scholar
  25. Dane DS, Cameron CH, Briggs M (1970) Virus-like particles in serum of patients with Australia antigen-associated hepatitis. Lancet 1:695CrossRefPubMedGoogle Scholar
  26. Da Villa G, Piazza M, Iorio R et al (1992) A pilot model of vaccination against hepatitis B virus suitable for mass vaccination campaigns in hyperendemic areas. J Med Virol 36:274–278CrossRefPubMedGoogle Scholar
  27. Da Villa G, Picciottoc L, Elia S et al (1995) Hepatitis B vaccination: Universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field. Vaccine 13:1240–1243CrossRefPubMedGoogle Scholar
  28. De la Torre J, Esteban R (1995) Implementing universal vaccination programs: Spain. Vaccine 13:72–74CrossRefGoogle Scholar
  29. Desmyter J, Colaert J, DeGroote G et al (1983) Efficacy of heat-inactivated hepatitis B vaccine in hemodialysis patients and staff: double blind placebo-controlled trial. Lancet 2:1323–1328CrossRefPubMedGoogle Scholar
  30. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359(14):1486–1500CrossRefPubMedGoogle Scholar
  31. Drew JS, London WT, Lustbader ED (1978) Hepatitis B virus and sex ratio of offspring. Science 201:687CrossRefPubMedGoogle Scholar
  32. Felton C, Lustbader ED, Merten C et al (1979) Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 76:2438–2441CrossRefPubMedGoogle Scholar
  33. Findley GM, MacCallum FO (1937) Note on acute hepatitis and yellow fever immunization. Trans R Soc Trop Med Hyg 51:297–308CrossRefGoogle Scholar
  34. Francis DP, Hadler SC, Thompson SE et al (1982) The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 97:362–366PubMedGoogle Scholar
  35. Gatcheva N, Vladimirova N, Kourtchatova A (1995) Implementing universal vaccination programs: Bulgaria. Vaccine 13:82–83Google Scholar
  36. Ginsberg GM, Shouval D (1992) Cost-benefit analysis of a nationwide neonatal inoculation program against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health 46:597–594CrossRefGoogle Scholar
  37. Gupta, MD (2008) Does hepatitis B infection or son preference explain the bulk of gender imbalance in China. http://www-wds.worldbank.org. Accessed 15 Aug 2008
  38. Havens WP (1947) The etiology of infectious hepatitis. JAMA 134:653–655Google Scholar
  39. Hepeng J (2008) A controversial bid to thwart the “Cantonese Cancer” Science 321:1154–1155CrossRefPubMedGoogle Scholar
  40. Hilleman M (1971) Personal communicationGoogle Scholar
  41. Kao JH, Hsy HM, Shau WY et al (2001) Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 139:349–352CrossRefPubMedGoogle Scholar
  42. Kellner A (1985) Reflections on Wolf Szmuness. Prog Clin Biol Res 182:3–10PubMedGoogle Scholar
  43. Krugman S (1986) The Willowbrook hepatitis studies revisited: Ethical aspects. Rev Infect Dis 8(1):157–162PubMedGoogle Scholar
  44. Krugman S, Giles JP, Hammond J (1967) Infectious hepatitis: Evidence for 2 distinctive clinical, epidemiological and immunological types of infection. JAMA 200:365–373CrossRefPubMedGoogle Scholar
  45. Krugman S, Giles JP, Hammond J (1971) Viral hepatitis, type B (MS-2 strain): Studies on active immunization. JAMA 217: 41–45CrossRefPubMedGoogle Scholar
  46. Lin MJ, Luoh MC (2006) Can hepatitis B mothers account for the number of missing women? Evidence from three million newborns in Taiwan. National Taiwan University. http://homepage.ntu.edu.tw/∼luohm/missingwomen.pdf. Accessed 10 Aug 2008
  47. London WT, DiFiglia M, Sutnick AI et al (1969) An epidemic of hepatitis in a chronic-hemodialysis unit. Australia antigen and differences in host response. N Engl J Med 281:571–578CrossRefPubMedGoogle Scholar
  48. London WT, Drew JS, Lustbader ED et al (1977) Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 12:51–58CrossRefPubMedGoogle Scholar
  49. London WT, Blumberg BS (1985) Comments on the role of epidemiology in the investigation of hepatitis B virus. Epidemiol Rev 7:59–79PubMedGoogle Scholar
  50. Lürman I (1885) Eine Icterusepidemie. Berlin Klin Wochenschr 22:20–41Google Scholar
  51. Lustbader ED, London WT, Blumberg BS (1976) Study design for a hepatitis B vaccine trial. Proc Natl Acad Sci USA 73:955–959CrossRefPubMedGoogle Scholar
  52. Marshall E (1998) A shadow falls on hepatitis B vaccination effort. Science 281:630–631CrossRefPubMedGoogle Scholar
  53. Maupas P, Chiron VP, Barn F et al (1981) Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier in children: controlled trial in an endemic area (Senegal). Lancet 1:289–292CrossRefPubMedGoogle Scholar
  54. McAleer WJ, Buynak EB, Maigetter RZ et al (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307:178–180CrossRefPubMedGoogle Scholar
  55. McMahon B, Mandsager R, Wainwright K et al (1996) The Alaska native hepatitis B control program. Proc. IX triennial international symposium on viral hepatitis and liver disease, Rome, 21–25 April 1996Google Scholar
  56. Merigan T (1997) Personal communicationGoogle Scholar
  57. Okochi DJ, Murakami S (1968) Observations on Australia antigen in Japanese. Vox Sang 15:374–385CrossRefPubMedGoogle Scholar
  58. Okochi DJ, Murakami S, Nonomiya K et al (1970) Australia antigen, transfusion and hepatitis. Vox Sang 18:289–300CrossRefGoogle Scholar
  59. Oster E (2005) Hepatitis B and the case of the missing women. J Polit Econ 113:1163–1216CrossRefGoogle Scholar
  60. Prince AM (1968) An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 60:814–821CrossRefPubMedGoogle Scholar
  61. Seefe LB, Beebe GW, Hoofnagle JH et al (1987) A serologic follow-up of the 1942 epidemic of post-transfusion hepatitis in the United States Army. N Engl J Med 316:965–970CrossRefGoogle Scholar
  62. Senior JR, Sutnick AI, Goeser E et al (1974) Reduction of post-transfusion hepatitis by exclusion of Australia antigen from donor blood in an urban public hospital. Amer J Med Sci 267:171–177CrossRefPubMedGoogle Scholar
  63. Sherker AH, Marion PL (1991) Hepadna viruses and hepatocellular carcinoma, Annu Rev Microbiol 45:475–507PubMedGoogle Scholar
  64. Sutnick AI, Blumberg BS, Lustbader ED (1974) Elevated serum iron levels and persistent Australia antigen (HBsAg). Ann Intern Med 81:855–856PubMedGoogle Scholar
  65. Szmuness W (1980) Personal communicationGoogle Scholar
  66. Szmuness W, Much MI, Prince AM et al (1975) On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med 83:489–495PubMedGoogle Scholar
  67. Szmuness W, Harley EJ, Ikram H et al (1978) Socio-demographic aspects of the epidemiology of hepatitis B. In: Vyas G, Cohen SN, Schmid R (eds) Viral hepatitis. Franklin Institute Press, PhiladelphiaGoogle Scholar
  68. Szmuness W, Stevens CE, Harley EJ et al (1980) Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303:833–841CrossRefPubMedGoogle Scholar
  69. Szmuness W, Stevens CE, Harley EJ et al (1981) A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B); a final report. Hepatology 8:119–121Google Scholar
  70. Van Damme P, Vorsters A (2002) Hepatitis B control in Europe by universal vaccination programmes: The situation in 2001. J Med Virol 67:433–439CrossRefPubMedGoogle Scholar
  71. Vierucci A, Bianchini AM, Morgese G et al (1968) L’antigene Austrlia. I Rapporte con l’epatite infettiva e da siero. Una ricerca in pazienta pediatrici. Pediatria Int 18:3–11Google Scholar
  72. Zuckerman AJ (1976) Twenty-five centuries of viral hepatitis. Rush-Presbyterian-St. Luke’s Medical Bulletin 15:57Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Fox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations